|Bid||42.47 x 2200|
|Ask||42.48 x 1000|
|Day's Range||42.41 - 42.76|
|52 Week Range||38.97 - 45.62|
|Beta (3Y Monthly)||0.40|
|PE Ratio (TTM)||21.89|
|Forward Dividend & Yield||1.74 (4.30%)|
|1y Target Est||52.00|
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.
TORONTO , June 11, 2019 /CNW Telbec/ - The 22nd edition of The Sanofi Canada Healthcare Survey uncovered gaps in knowledge that can serve to help guide decision-making among employers who provide health benefit plans to employees. A persistent gap is employers' underestimation of the presence of chronic disease in their workforce, which suggests they may also underestimate the negative impact of unmanaged disease on productivity.
With big pharma companies grappling with fundamental as well as geopolitical issues — including aging pipelines, key blockbuster drugs going off patent and a U.S. clampdown on drug pricing — many have turned to new leadership in recent years to reinvigorate growth. Sanofi has a mandatory 65-year-old retirement age for its CEO.
There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring.Source: Shutterstock Here's what you need to know about Sanofi's (NASDAQ:SNY) new CEO. * The new Sanofi CEO is Paul Hudson. * He will be taking over the role of CEO from Brandicourt starting on Sept. 1, 2019. * Hudson's most recent work includes serving as the CEO of Novartis Pharmaceuticals (NYSE:NVS) and being a member on the Novartis Executive Committee. * The new Sanofi CEO also has plenty of experience working with pharmaceutical companies over the last 28 years. * Some of his major previous employers include Schering Plough, Astra Zeneca (NYSE:AZN) and Novartis. * This has given him plenty of experience working in the markets of the U.S., Japan and Europe. * It has also awarded him the experience needed to handle leadership through his previous management roles. * Paul Hudson will also be moving to Paris, France to serve in his role as CEO of the company, which has its headquarter there. * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% Serge Weinberg, Chairman of the Board of Directors for Sanofi, has this to say about the change.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"We are very pleased that Paul Hudson has agreed to join Sanofi. His skills and experience give him all the assets he needs to accelerate growth and lead the Group's adaptation to new strategic challenges, particularly in the areas of Research and Development and digital. His human values will enable him to mobilize all the energies and increase the agility, that a group such as Sanofi needs, to face the new challenges of our industry and the changes in healthcare systems around the world."SNY stock was up 5% as of Friday morning. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% * 7 Stocks to Buy That Don't Care About Tariffs * 5 Healthcare Stocks to Pick Up From the Wreckage As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post New Sanofi CEO 2019: 8 Things to Know About Paul Hudson appeared first on InvestorPlace.
Bringing in Paul Hudson as its next chief executive officer will help the French pharma giant bolster its pipeline of medicines and deal with growing U.S. pressure on drug prices. The 51-year-old British executive will take over in September from Olivier Brandicourt, 63, who’s retiring. Hudson has led Novartis’s pharma unit since 2016 and is credited with launching key medicines such as psoriasis treatment Cosentyx, which may become its top product this year with a projected $3.5 billion in sales.
Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 6) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: ...
* Hudson from Novartis to join Sanofi from Sept. 1 * Current CEO Brandicourt to retire * Shares up almost 5 percent (Adds share price, comment) By Matthias Blamont PARIS, June 7 (Reuters) - Sanofi has poached Paul Hudson from Novartis to replace Chief Executive Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday, helping send its shares almost 5 percent higher. Hudson, who is British, will take over on Sept. 1, Sanofi said, confirming a Reuters report published on Thursday and marking the latest move by a Novartis executive to a competitor.
European stocks were on course to notch their best weekly performance in two months on Friday as a jump in shares of French pharma giant Sanofi added to the positive mood created by expectations of more moves by central banks to stir growth. France's CAC 40 outperformed its peers with a 1.2% rise, helped by a 4.5% jump in Sanofi after the company appointed Swiss rival Novartis' executive Paul Hudson as its new boss.
French drugmaker Sanofi has announced that a top executive from Swiss rival Novartis will succeed Olivier Brandicourt as CEO. Paul Hudson, who was most recently chief executive of the Novartis pharmaceuticals business and member of the executive committee of the overall group, will take over on September 1. since Sanofi’s diabetes treatments lost patent protection and came under pressure from cheaper rivals.
European stocks were in recovery mode on Friday after a cautious message from the European Central Bank hit investors' appetite for risk in the previous session, with traders eyeing a U.S. jobs report and U.S. trade tussles with Mexico for fresh direction. Automakers climbed on a report that U.S. President Donald Trump could delay the tariffs he had threatened to put on Mexican goods as soon as this coming Monday, while French drugmaker Sanofi gained on its appointment of a new chief executive. France's CAC 40 outperformed its euro-peers with a 0.9%, helped by French pharma giant Sanofi.
Sanofi has appointed Novartis executive Paul Hudson to replace CEO Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday. Hudson will take over on Sept. 1, Sanofi said, confirming a Reuters report published on Thursday and marking the latest transfer of a Novartis executive to a competitor. UK-born Hudson, 51, has been CEO of the Novartis Pharmaceuticals, one of the Swiss company's three main divisions, since 2016.
CytoSen Therapeutics Inc., which creates anti-cancer cell treatments, was acquired for a stock transaction by Netherlands-based Kiadis Pharma NV that could be valued at up to $70 million, depending on stock prices throughout the deal.Kiadis will include an upfront consideration of 1.94 million shares of its stock as part of the deal. Kiadis shares were trading at $7.70 as of June 6, according to Yahoo!Finance, The acquisition, announced on April 17, comes as as both companies are working on cell-based technology that helps fight cancer naturally, CytoSen co-founder Robert Igarashi told Orlando Business Journal. "It's fair to say, Orlando is continuing to be an up-and-coming life sciences center.
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.
Shares of Emergent (EBS) rise after the company gets a 10-year HHS contract valued at roughly $535 million to dispense VIGIV product to the U.S. government for supporting its smallpox awareness drive.
Germany's highest civil court on Tuesday rejected French drugmaker Sanofi's bid to fend off a legal challenge by U.S. rival Amgen against Sanofi's cholesterol drug Praluent. In the latest setback for Sanofi in the drawn-out patent dispute with Amgen, which is selling its rival drug Repatha, the German court ruled that Sanofi was not entitled to a special licence that would have protected its Praluent business. Officials at Sanofi did not have an immediate comment.
Companies like Iovance Biotherapeutics Inc., MacroGenics Inc. and Nektar Therapeutics will be in the spotlight when the annual event kicks off Friday in Chicago. “Sentiment heading into the conference is notably bland, but there should still be enough stock-specific events to keep us on our toes,” Baird analyst Brian Skorney said in a note to clients. The Nasdaq Biotechnology Index has fallen 12% from its March highs as investors lamented some high-profile drug failures and a lack of big deals.
BioMarin (BMRN) announces significant reduction in annual bleed rate in phase III study evaluating gene therapy, valoctocogene roxaparvovec, in hemophilia A patients. However, investors are skeptical.